Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers

HIV Medicine

Volumn 10, Issue 5, 2009, Pages 318-327

  Tomaka, Frank ^a   Lefebvre, E ^b   Sekar, V ^a   Van Baelen, B ^c   Vangeneugden, T ^c   Vandevoorde, A ^c   Miralles, G Diego ^c  

^a Tibotec Inc   (United States)

^b Janssen Cilag BV Netherlands   (Netherlands)

^c TIBOTEC BVBA   (Belgium)

Author keywords

Atazanavir; Darunavir; HIV; Lipids; Metabolic; Protease inhibitors; TMC114

Indexed keywords

ATAZANAVIR; CHOLESTEROL; DARUNAVIR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; JAUNDICE; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; URTICARIA; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; BLOOD GLUCOSE; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FASTING; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HUMANS; INSULIN; LIPID METABOLISM; LIPOPROTEINS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; SULFONAMIDES; TRIGLYCERIDES; YOUNG ADULT;

EID: 65449168722     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00690.x     Document Type: Article

References (40)

1. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
2. Katlama C, Esposito R, Gatell JM et al. Efficacy and safety of TMC114/ ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21: 395-402.
3. Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21: F11-F18.
4. Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1168-1178.
5. Gulick RM. New antiretroviral drugs. Clin Microbiol Infect 2003; 9: 186-193.
6. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
7. Carr A. HIV lipodystrophy: Risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 (Suppl. 1): S141-S148.
8. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev 2006; 8: 191-203.
9. Möbius U, Lubach-Ruitman M, Castro-Frenzel B et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005; 39: 174-180.
10. Murphy RL, Sanne I, Cahn P et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results. AIDS 2003; 17: 2603-2614.
11. Johnson M, Grinsztejn B, Rodriguez C et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19: 685-694.
12. De Wit S, Poll B, Nescoi C, Clumeck N. Atazanavir has a better impact on lipid profiles than fosamprenavir and lopinavir in patients matched for baseline triglycerides and cholesterol. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2006 [Abstract P127].
13. Tibotec Inc. PREZISTA® (darunavir) Prescribing Information. October 2006 [cited 14 March 2007]. Available at: http://www.prezista.com. Accessed on 14 March 2007.
14. PREZISTA® (darunavir): Summary of product characteristics (EMEA). Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/prezista/ prezista.htm. Accessed on 18 April 2007.
15. Boffito M, Moyle G, Hill A et al. The pharmacokinetic profile of darunavir with low-dose ritonavir in various multiple-dose regimens over 120 hours. 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, FL, April 2008 [Abstract P31].
16. De Meyer S, Spinosa-Guzman S, Vangeneugden T, de Béthune MP, Miralles D. Efficacy of darunavir (DRV)/r 800/100mg qd in patients with low DRV resistance. 5th European HIV Drug Resistance Workshop. Cascais, Portugal, March 2007 [Abstract 48].
17. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-1052.
18. Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. J Am Med Assoc 2003; 289: 2978-2982.
19. Jones R, Sawleshwarkar S, Michailidis C et al. Impact of antiretroviral choice on hypercholesterolaemia events: The role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005; 6: 396-402.
20. Shlay JC, Bartsch G, Peng G et al. Long-term body composition and metabolic changes in antiretroviral naïve persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007; 44: 506-517.
21. Lee GA, Seneviratne T, Noor MA et al. The metabolic effects of lopinavir/ ritonavir in HIV-negative men. AIDS 2004; 18: 641-649.
22. Noor MA, Parker RA, O'Mara E et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18: 2137-2144.
23. Noor MA, Lo JC, Mulligan K et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15: F11-F18.
24. Schwarz JM, Lee GA, Park S et al. Indinavir increases glucose production in healthy HIV-negative men. AIDS 2004; 18: 1852-1854.
25. AIDS Clinical Trials Group. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, December 2004 [cited 26 March 2006]. Available at: http://www.aactg.org/ science_sciguidelines.asp Accessed on 14 March 2007.
26. Sips L, Bouche MP. Validation (full) of an LC-MS/MS method for the determination of TMC114 (R319064), ritonavir (R115891) and lopinavir (R366619) in human heparin plasma. Johnson & Johnson Pharmaceutical Research & Development Bioanalytical Report R319064/R115891/BA819.
27. Van Hall G. The validation of atazanavir in human heparin plasma using LC-MS/MS. ABL Validation Report 5165, December 2004.
28. Bonnet E, Delpierre C, Sommet A et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: Proposal of reference values for defining lipodystrophy. J Clin Densitom 2005; 8: 287-292.
29. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493-2505.
30. Fontas E, van Leth F, Sabin CA et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189: 1056-1074.
31. Thiebaut R, Dabis F, Malvy D et al. for the Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. J Acquir Immune Defic Syndr 2000; 23: 261-265.
32. Sullivan AK, Nelson MR. Marked hyperlipidemia on ritonavir therapy. AIDS 1997; 11: 938-939.
33. Périard D, Telenti A, Sudre P et al. for the Swiss HIV Cohort Study. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100: 700-705.
34. British Cardiac Society, British Hypertension Society, diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl. 5): V1-v52.
35. Von Hentig N, Rottmann C, Haberl A et al. Pharmacokinetic interactions of atazanavir and saquinavir in a ritonavir boosted protease inhibitor therapy regimen. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2004 [Abstract P262].
36. Boffito M, Back D, Kurowski M et al. Pharmacokinetics (PK) of saquinavir hard gel (sqv)/ritonavir (rtv) with atazanavir (atv) or fosamprenavir (fpv) in HIV-positive patients. 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy, April 2004 [Abstract 4.5].
37. Boffito M, Kurowski M, Kruse G. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291-1297.
38. Bristol-Myers Squibb Co. Reyataz® (atazanavir sulfate) Prescribing Information October 2006 [cited 14 March 2007]. Available at: http://www.reyataz.com. Accessed on 14 March 2007.
39. Ortiz R, DeJesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-1397.
40. Goldsmith DR, Perry CM. Atazanavir. Drugs 2003; 63: 1679-1693.